Cargando…

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis

OBJECTIVES: People with RA taking DMARDs require safety monitoring to identify potential side effects. The aim of this study was to explore the perspectives of patients and family members on DMARD monitoring and how the associated treatment burden could be minimized to optimize concordance and safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryan, Sarah, Bullock, Laurna, Manning, Fay, A. Chew-Graham, Carolyn, Paskins, Zoe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307943/ https://www.ncbi.nlm.nih.gov/pubmed/37396879 http://dx.doi.org/10.1093/rap/rkad054

Ejemplares similares

Exploring the physical, psychological and social well-being of people with rheumatoid arthritis during the coronavirus pandemic: a single-centre, longitudinal, qualitative interview study in the UK
por: Ryan, Sarah, et al.
Publicado: (2022)

Incorporating FRAX into a nurse-delivered integrated care review: a multi-method qualitative study
por: Hawarden, Ashley, et al.
Publicado: (2023)

Exploring the longer-term impact of the COVID-19 pandemic on physical and mental health of people with inflammatory rheumatic diseases: a cross-sectional survey
por: Hider, Samantha, et al.
Publicado: (2023)

Perceptions of risk in people with inflammatory arthritis during the COVID-19 pandemic
por: Ryan, Sarah, et al.
Publicado: (2022)

Acceptability of, and preferences for, remote consulting during COVID-19 among older patients with two common long-term musculoskeletal conditions: findings from three qualitative studies and recommendations for practice
por: Paskins, Zoe, et al.
Publicado: (2022)

The challenge of pain identification, assessment, and management in people with dementia: a qualitative study
por: Bullock, Laurna, et al.
Publicado: (2020)

Public priorities for osteoporosis and fracture research: results from a focus group study
por: Hawarden, Ashley, et al.
Publicado: (2020)

Clinical decision-making in remote rheumatology consultations: a service evaluation of new patient and inflammatory rheumatic disease follow-up appointments
por: Tarar, Ahmed B, et al.
Publicado: (2021)

Digital exclusion as a potential cause of inequalities in access to care: a survey in people with inflammatory rheumatic diseases
por: Hider, Samantha, et al.
Publicado: (2023)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

The approach to managing perinatal anxiety: A mini-review
por: Silverwood, Victoria Anne, et al.
Publicado: (2022)

A Treatise on Rheumatism and Rheumatoid Arthritis
Publicado: (1892)

Osteoporosis and fracture as risk factors for self-harm and suicide: a systematic review and meta-analysis
por: Manning, Fay M, et al.
Publicado: (2023)

Non-pharmacological interventions for the management of perinatal anxiety in primary care: a meta-review of systematic reviews
por: Silverwood, Victoria, et al.
Publicado: (2023)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Cataphoresis in the Treatment of Gout, Rheumatism, and Rheumatoid Arthritis
por: Begg, Charles
Publicado: (1902)

The Differential Diagnosis of Gout, Rheumatism, and Rheumatoid Arthritis
por: Luff, Arthur P.
Publicado: (1900)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis
por: Wood, Patrick R, et al.
Publicado: (2018)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
por: Heidari, Behzad, et al.
Publicado: (2012)

Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
por: Khalid, Sabeen, et al.
Publicado: (2019)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
por: Arias de la Rosa, Iván, et al.
Publicado: (2021)

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis
por: Si, Lulu, et al.
Publicado: (2022)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Vertebral fracture as a risk factor for self-harm: a retrospective cohort study
por: Prior, James A., et al.
Publicado: (2021)

Developing a model Fracture Liaison Service consultation with patients, carers and clinicians: a Delphi survey to inform content of the iFraP complex consultation intervention
por: Bullock, Laurna, et al.
Publicado: (2021)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Improving uptake of Fracture Prevention drug treatments: a protocol for Development of a consultation intervention (iFraP-D)
por: Paskins, Zoe, et al.
Publicado: (2021)

A COMPARATIVE STUDY OF SUBCUTANEOUS NODULES IN RHEUMATIC FEVER AND RHEUMATOID ARTHRITIS
por: Dawson, M. H.
Publicado: (1933)

The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
por: Chou, CT, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jlj1baoceb2tss7fg4a5n267af